Clinical Trial Update: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors [Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 2 study assessing the combination of nivolumab, ipilimumab, and cabozantinib for various rare genitourinary tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Chromophobe Renal Cell Carcinoma
• Penile Cancer
• Prostate Cancer
• Renal Cell Carcinoma
• Testicular Cancer
• Urethral Cancer
• Urothelial Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Status: RECRUITING